{"DataElement":{"publicId":"3008113","version":"2","preferredName":"Disease or Disorder Best Outcome of Therapy Amyloidosis Cardiac Status Type","preferredDefinition":"A description of the best cardiac response to therapy for amyloidosis.","longName":"2946463v1.0:3008093v1.5","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3008093","version":"1.5","preferredName":"Amyloidosis Cardiac Status Type","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands._Having to do with the heart._A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"3008093v1.5","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not assessed","valueDescription":"Not Done","ValueMeaning":{"publicId":"3104692","version":"1","preferredName":"Not Done","longName":"3104692v1.00","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or not been completed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"88084310-6796-6259-E040-BB89AD4311C3","latestVersionIndicator":"Yes","beginDate":"2010-06-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-02","modifiedBy":"RAGUNATHANU","dateModified":"2022-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"8E5FB491-C4A6-4E7C-E053-F662850A2EA9","beginDate":"2010-02-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"Not evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"8E5FB491-C4B0-4E7C-E053-F662850A2EA9","beginDate":"2010-02-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5FB491-C4BA-4E7C-E053-F662850A2EA9","beginDate":"2014-03-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"No response / stable disease","valueDescription":"No response/stable disease","ValueMeaning":{"publicId":"4242633","version":"1","preferredName":"No response/stable disease","longName":"4242633","preferredDefinition":"Does not meet the criteria for cardiac response or cardiac progression.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F520027D-BBB7-924A-E040-BB89AD430F86","latestVersionIndicator":"Yes","beginDate":"2014-03-21","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-03-21","modifiedBy":"COOPERM","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5FB491-C4CE-4E7C-E053-F662850A2EA9","beginDate":"2014-03-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"Cardiac response","valueDescription":"Cardiac response","ValueMeaning":{"publicId":"4873115","version":"1","preferredName":"Cardiac response","longName":"4873115","preferredDefinition":"NT-proBNP response (>30% and >300 ng/l decrease in patients with baseline NT-proBNP >= 650ng/l) or New York Heart Association (NYHA) class response (>= 2 class decrease in subjects with baseline NYHA class 3 or 4)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18BB0C20-E55D-9F97-E050-BB89AD433E31","latestVersionIndicator":"Yes","beginDate":"2015-06-17","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-06-17","modifiedBy":"KUMMEROA","dateModified":"2019-12-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5FB491-C4D8-4E7C-E053-F662850A2EA9","beginDate":"2011-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"},{"value":"Cardiac progression","valueDescription":"Cardiac progression","ValueMeaning":{"publicId":"6823744","version":"1","preferredName":"Cardiac progression","longName":"6823744","preferredDefinition":"NT-proBNP progression (>30% and >300 ng/l increase) or cTn progression (>= 33% increase) or ejection fraction progression (>= 10% decrease)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5FC3B8-D66D-33A1-E053-F662850AF61A","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E5FC3B8-D686-33A1-E053-F662850AF61A","beginDate":"2019-07-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-23","modifiedBy":"ONEDATA","dateModified":"2019-07-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3008092","version":"1","preferredName":"Amyloidosis Cardiac Status Type","preferredDefinition":"A group of diseases in which protein is deposited in specific organs (localized amyloidosis) or throughout the body (systemic amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary amyloidosis often affects the spleen, kidneys, liver, and adrenal glands.:Having to do with the heart.:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C2868:C13306:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cardiac","conceptCode":"C13306","definition":"Having to do with the heart.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F18900C-CC2C-E3F0-E040-BB89AD436777","latestVersionIndicator":"Yes","beginDate":"2010-02-08","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-08","modifiedBy":"ONEDATA","dateModified":"2010-02-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5FB491-C48F-4E7C-E053-F662850A2EA9","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-23","modifiedBy":"KUMMEROA","dateModified":"2020-02-03","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964910","version":"1","longName":"2117r1: Amyloidosis Post-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"},{"name":"amy_post_bst_card_rsp","type":"NMDP_FN","context":"NHLBI"},{"name":"PCDpost_amy_hema_organ_card_best_resp","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What is the best cardiac outc","type":"Preferred Question Text","description":"What is the best cardiac outcome of therapy for amyloidosis?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:3008113","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis > AssessedResultRelationship > PerformedObservation > PerformedClinicalinterpretation.value = \"best result\" AND PerformedDiagnosis.value = \"cardiac disease\"","url":null,"context":"NHLBI"},{"name":"Specify the recipient's best cardiac response to the HCT","type":"Application Standard Question Text","description":"Specify the recipient's best cardiac response to the HCT","url":null,"context":"NHLBI"},{"name":"Specify the recipient's best cardiac response to the HCT","type":"Alternate Question Text","description":"Specify the recipient's best cardiac response to the HCT","url":null,"context":"NHLBI"},{"name":"Specify the recipient's best cardiac response","type":"Alternate Question Text","description":"Specify the recipient's best cardiac response","url":null,"context":"NHLBI"},{"name":"Specify the recipient's best cardiac response to the HSCT","type":"Alternate Question Text","description":"Specify the recipient's best cardiac response to the HSCT","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E5FB491-C4ED-4E7C-E053-F662850A2EA9","latestVersionIndicator":"Yes","beginDate":"2019-07-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-07-23","modifiedBy":"MALUMK","dateModified":"2021-02-24","changeDescription":". System generated def displayed as alt def.; System generated def displayed as alt def. AQT added for 2116r5. 02/24/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}